Activated protein C resistance and
factor V Leiden mutation can be associated with first as well as secondtrimester recurrent pregnancy loss.
Individuals who are heterozygous for the
Factor V Leiden mutation carry a risk of venous thrombosis five to seven times higher than that of the general population; homozygous subjects have a risk 80 times higher.
[36] determined the prevalence of the
factor V Leiden mutation in 73 patients with postthrombotic and nonpostthrombotic venous ulcers.
(22.) Haslam N, Standen GR, Probert CS: An investigation of the association of the
factor V Leiden mutation and inflammatory bowel disease.
The
factor V Leiden mutation is the most frequent cause of familial thrombosis and vWD is the most common inherited bleeding disorder.
Factor V Leiden mutation is present in the 4-6% of the general population and is the most common inherited cause of the syndrome accounting for the 40-50% of cases (1).
(16) Since lupus anti coagulant may be a potential interferent in the modified assay, patients with lupus anticoagulant should be evaluated for the
factor V Leiden mutation by genetic testing.
The
factor V Leiden mutation is the most common genetic thrombophilia: the heterozygous form, found in 5%-8% of the normal population, increases the risk of VTE five-fold, whereas the rarer homozygous form confers an 18-fold risk increase.
American College of Medical Genetics consensus statement on
factor V Leiden mutation testing.
Prothrombin 20210 G: a mutation and
Factor V Leiden mutation in women with a history of severe preeclampsia and (H)ELLP syndrome.
Objectives: To determine the frequency of Protein C Protein S (PC and PS) antithrombin deficiency (AT III) and
Factor V Leiden mutation (FVL) as a cause of thrombophilia in the patients with venous thromboembolism (VTE) and cerebrovascular accident (CVA).